TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism
Background Transforming growth factor-β (TGFβ) is emerging as a promising target for cancer therapy, given its ability to promote progression of advanced tumors and to suppress anti-tumor immune responses. However, TGFβ also plays multiple roles in normal tissues, particularly during organogenesis,...
Автори: | Canè, S, Van Snick, J, Uyttenhove, C, Pilotte, L, Van den Eynde, BJ |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
BMJ Publishing Group
2021
|
Схожі ресурси
Схожі ресурси
-
TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism
за авторством: Stefania Canè, та інші
Опубліковано: (2021-02-01) -
Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance
за авторством: Hennequart, M, та інші
Опубліковано: (2017) -
Constitutive IDO1 expression in human tumors is driven by cyclooxygenase-2 and mediates intrinsic immune resistance.
за авторством: Hennequart, M, та інші
Опубліковано: (2017) -
Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer
за авторством: Aditi Gupta, та інші
Опубліковано: (2021-11-01) -
TGF-β Neutralization Enhances AngII-Induced Aortic Rupture and Aneurysm in Both Thoracic and Abdominal Regions.
за авторством: Xiaofeng Chen, та інші
Опубліковано: (2016-01-01)